DiagnoLung®

AMADIX Test de cáncer de pulmón

What is DiagnoLung®?

DiagnoLung®, is an innovative, non-invasive early detection test for lung cancer

It can also be used as a tool for a high-risk screening population in combination with Low Dose Computed Tomography (LDCT).

A simple blood-based test

Learn more

Product characteristics

Learn more

Request a test

Learn more
Diagnolung
DiagnoLung

How does it work?

Beyond diagnosis

DiagnoLung® identifies and measures proteins which are differentially expressed in blood samples of individuals with Lung Cancer

  • Biomarker signature
  • Non-invasive test in blood
  • Easy, low cost and a common technique for hospitals and laboratories
  • Confirmation of lung cancer and risk assessment of Incidental Pulmonary Nodules (IPNs) in positive Low Dose Computed Tomography (LDCT) patients and that are incidentally detected.

High potential

Superior accuracy

Very simple

No previous preparation

Reliable

Disruptive

DiagnoLung® characteristics

Learn more about DiagnoLung®

DiagnoLung is intended for:

  1. The risk assessment for malignancy of Incidental pulmonary nodules (IPNs):
    • Incidentally detected
    • Positive Low Dose Computed Tomography patients, improving the performance of the Low Dose Computed Tomography screening program
  2. The confirmation of lung cancer in inconclusive diagnostics. 

In patients with indeterminate pulmonary nodules, between 6 and 30 mm, DiagnoLung would allow physicians to identify patients with likely benign nodules who would become candidates for serial Computed Tomography (CT) monitoring within 2 years.

In a screening context, DiagnoLung is indicated to confirm positive Low Dose Computed Tomography (LDCT) results that may indicate the presence of lung cancer and should be confirmed with an invasive test (biopsies). 

Performed in conjunction with a biopsy, DiagnoLung can be used to confirm cancer in patients with inconclusive cytological and histological analysis (in a clinical context, it is not possible to confirm the diagnosis in up to 50% of first bronchoscopies).

It is not a replacement for diagnostic methods or the monitoring of high-risk individuals (50 to 80 years old and in fairly good health, who currently smoke or who have quit in the past 15 years and have at least a 20 pack/year smoking history).

Diagnolung

Colorectal cancer (CRC) is the 3rd most frequent tumor and is usually detected in late stages

1,880,400

New cases of CRC in the world 20201

2020

1,880M

2022

2,880M

The incidence of cancer in the world will increase by 53,2% in the next 20 years1

1 Globocan 2020 Colorectal Cancer fact sheet

Developing IA algorithms for early cancer diagnosis

Aligned with our mission, we are working on combining our blood-based test using molecular biomarkers with colon cancer risk factors identified by Artificial Intelligence and Big Data tools, based on medical history and individual habits.

We continue to go further and are exploring the infinite possibilities that clinical records and patient lifestyle data offer through the latest Artificial Intelligence (AI) and Advanced Data Analytical Tools. This will allow us to identify new risk factors to develop predictive models which will help us anticipate hidden underlying cancer risk factors and help improve the quality of life and survival of cancer patients.

Artificial Intelligence (AI) and Advanced Data Analytical tools will serve AMADIX to identify hidden underlying cancer risk factors and develop predictive models to include in PreveCol® algorithms, as well as define new screening populations, in which the eligibility criterion is not based solely on age.

  • Improve performance and accuracy
  • Data security and anonymous
  • New target screening population

Revolutionary science

Rigorous protection

Duly protected internationally through two family patents.

*Pending patent in China, Canada, and Australia

Intellectual Property

Glossary

All about Cancer

Lung Cancer

Lung cancer is one of the most important health problems worldwide and the leading cause of deaths from cancer (1.79M in 2020). More than 2 million lung cancers are diagnosed every year.  The incidence of lung cancer in Spain in 2020 was 63.4 cases per 100,000 inhabitants (29,188 total cases).
Lung cancer incidence continues to grow with an estimated 3.25 million new cases expected worldwide by 2035 (…)
Read more

Prevention

In medicine, prevention is the measures taken to reduce the chances of developing an illness, like getting vaccinated. In cancer, prevention is the best way to reduce the chances of having cancer, and if you have it, it is the best way to detect it in its early stages, thus leading to a higher survival rate.
There are different levels of prevention (…)
Read more

Screening

Early detection, through screening programs, is essential for cancer control. Screening programs consist of carrying out diagnostic tests on people who are initially healthy. For some time now, early detection of lung cancer with low-dose computerized tomography (LDCT) has been proving to be effective in reducing mortality in specific high-risk groups.
While mortality is declining for most cancers, lung cancer continues to rise worldwide, especially among women (…)
Read more

Do you want to request a test?

If you are a patient, please ask your physician how to get Prevecol® or tell them to contact us.

If you are a doctor, fill in this form to contact us and/or to request a test







    I have read and accept the Privacy policy

    This site is protected by Google's reCaptcha and its Privacy Policy and Terms of Service apply.

    Let’s extend
    people’s lives

    Come and join us to Detect cancer in blood.

    Contact Us

    Amadix